Phathom Pharmaceuticals, Inc.
PHAT$526M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaFLORHAM PARK427 employees
Drugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Dec 15, 2026
39wMarket Overview
Stock performance and key metrics
PHAT News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Amoxicillin
Helicobacter Pylori Infection
Lansoprazole
Erosive Esophagitis
Vonoprazan
Non-Erosive Gastro-Esophageal Reflux Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Amoxicillin | Phase 3 | Helicobacter Pylori Infection | - | - |
Lansoprazole | Phase 3 | Erosive Esophagitis | - | - |
Vonoprazan | Phase 3 | Non-Erosive Gastro-Esophageal Reflux Disease | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply